{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:29:22Z","timestamp":1790688562041,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.bulcan.2018.07.011","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T15:25:48Z","timestamp":1536679548000},"page":"967-980","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Prise en charge des m\u00e9lanomes oculaires, le minimum pour les oncologues"],"prefix":"10.1016","volume":"105","author":[{"given":"Thibaud","family":"Mathis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cassoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magali","family":"Tardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Piperno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauris","family":"Gastaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9mi","family":"Dendale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Maschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anh-minh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Bonnin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Baillif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Mouriaux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Jaspart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josette","family":"Dellis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Rosier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Herault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Pierre","family":"Caujolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Thariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2018.07.011_bib0265","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0161-6420(03)00078-2","article-title":"Incidence of uveal melanoma in the United States: 1973\u20131997","volume":"110","author":"Singh","year":"2003","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0270","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1016\/j.ophtha.2007.01.032","article-title":"Incidence of uveal melanoma in Europe","volume":"114","author":"Virgili","year":"2007","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0275","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/bjophthalmol-2013-303867","article-title":"Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma","volume":"98","author":"Cassoux","year":"2014","journal-title":"Br J Ophthalmol"},{"issue":"123","key":"10.1016\/j.bulcan.2018.07.011_bib0280","first-page":"1639","article-title":"Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report No.\u00a026","volume":"1960","author":"Diener-West","year":"2005","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0285","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"124","key":"10.1016\/j.bulcan.2018.07.011_bib0290","first-page":"1684","article-title":"The COMS randomized trial of iodine 125\u00a0brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No.\u00a028","volume":"1960","author":"Collaborative Ocular Melanoma Study Group","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0295","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.brachy.2011.01.006","article-title":"A 17-year retrospective study of institutional results for eye plaque brachytherapy of uveal melanoma using 125I, 103Pd, and 131Cs and historical perspective","volume":"10","author":"Leonard","year":"2011","journal-title":"Brachytherapy"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0300","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.ijrobp.2005.01.016","article-title":"Proton beam radiotherapy of choroidal melanoma: the Liverpool-Clatterbridge experience","volume":"62","author":"Damato","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0305","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S0161-6420(99)90456-6","article-title":"Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma","volume":"106","author":"Wilson","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0310","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.ejso.2009.02.016","article-title":"Surgical management of liver metastases from uveal melanoma: 16\u00a0years\u2019 experience at the Institut Curie","volume":"35","author":"Mariani","year":"2009","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0315","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ophtha.2015.12.024","article-title":"The Pediatric Choroidal and Ciliary Body Melanoma Study: a survey by the European Ophthalmic Oncology Group","volume":"123","author":"Al-Jamal","year":"2016","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000330613","article-title":"Diagnosis of uveal melanoma","volume":"49","author":"Kivel\u00e4","year":"2012","journal-title":"Dev Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0325","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/j.ijrobp.2006.01.020","article-title":"Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO)","volume":"65","author":"Dendale","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0330","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0360-3016(82)90530-2","article-title":"Precise positioning of patients for radiation therapy","volume":"8","author":"Verhey","year":"1982","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0335","first-page":"123","article-title":"The Bragg peak of proton beams for treatment of uveal melanoma","volume":"20","author":"Gragoudas","year":"1980","journal-title":"Int Ophthalmol Clin"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0340","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.ijrobp.2015.12.011","article-title":"Visual outcomes of parapapillary uveal melanomas following proton beam therapy","volume":"95","author":"Thariat","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0345","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.ijrobp.2009.07.1753","article-title":"Radiation dose-volume effects of optic nerves and chiasm","volume":"76","author":"Mayo","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0350","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0161-6420(99)90455-4","article-title":"Risk factors for radiation maculopathy and papillopathy after intraocular irradiation","volume":"106","author":"Gragoudas","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0355","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ajo.2016.04.024","article-title":"Antiangiogenic or corticosteroid treatment in patients with radiation maculopathy after proton beam therapy for uveal melanoma","volume":"168","author":"Seibel","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajo.2016.02.027","article-title":"Outcomes after proton beam therapy for large choroidal melanomas in 492\u00a0patients","volume":"165","author":"Bensoussan","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0365","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1001\/jamaophthalmol.2017.3805","article-title":"Long-term outcomes after proton beam irradiation in patients with large choroidal melanomas","volume":"135","author":"Papakostas","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0370","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2017.01.199","article-title":"Dry eye syndrome after proton therapy of ocular melanomas","volume":"98","author":"Thariat","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0375","doi-asserted-by":"crossref","first-page":"268","DOI":"10.5858\/2008-132-268-IM","article-title":"Iris melanoma","volume":"132","author":"Henderson","year":"2008","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0380","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0161-6420(00)00449-8","article-title":"Iris melanoma: risk factors for metastasis in 169\u00a0consecutive patients","volume":"108","author":"Shields","year":"2001","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0385","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ijrobp.2005.01.050","article-title":"Proton beam radiotherapy of iris melanoma","volume":"63","author":"Damato","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0390","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.ophtha.2017.10.009","article-title":"Proton beam therapy for iris melanomas in 107\u00a0patients","volume":"125","author":"Thariat","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0395","first-page":"1300","article-title":"Proton beam therapy for iris melanomas","volume":"20","author":"Lumbroso-Le Rouic","year":"2006","journal-title":"Eye Lond Engl"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0400","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/bjo.2003.029058","article-title":"The Zimmerman-McLean-Foster hypothesis: 25\u00a0years later","volume":"88","author":"Singh","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0405","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ophtha.2014.08.046","article-title":"Management of posterior uveal melanoma: past, present, and future: the 2014\u00a0Charles L Schepens lecture","volume":"122","author":"Shields","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0410","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00417-006-0477-1","article-title":"Survival after primary enucleation for choroidal melanoma: changes induced by the introduction of conservative therapies","volume":"245","author":"Gambrelle","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0415","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.ophtha.2003.09.028","article-title":"Conservation of eyes with choroidal melanoma by a multimodality approach to treatment: an audit of 1632\u00a0patients","volume":"111","author":"Damato","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0420","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ajo.2018.03.015","article-title":"Patient-reported outcomes and quality of life after treatment of choroidal melanoma: a comparison of enucleation versus radiotherapy in 1596\u00a0patients","volume":"193","author":"Damato","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0425","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0360-3016(99)00147-9","article-title":"Results of proton therapy of uveal melanomas treated in Nice","volume":"45","author":"Courdi","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"127","key":"10.1016\/j.bulcan.2018.07.011_bib0430","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/archophthalmol.2009.208","article-title":"Metastasis of uveal melanoma millimeter-by-millimeter in 8033\u00a0consecutive eyes","volume":"1960","author":"Shields","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0435","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.cancergen.2013.05.018","article-title":"Further evidence for germline BAP1\u00a0mutations predisposing to melanoma and malignant mesothelioma","volume":"206","author":"Cheung","year":"2013","journal-title":"Cancer Genet"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0440","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160092","article-title":"Imaging of ocular melanoma metastasis","volume":"89","author":"Balasubramanya","year":"2016","journal-title":"Br J Radiol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0445","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1001\/jamaophthalmol.2015.1766","article-title":"Potential role of soluble c-Met as a new candidate biomarker of metastatic uveal melanoma","volume":"133","author":"Barisione","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0450","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1002\/ijc.28436","article-title":"Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma","volume":"134","author":"Bidard","year":"2014","journal-title":"Int J Cancer"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0455","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1159\/000367715","article-title":"Adjuvant therapy of uveal melanoma: current status","volume":"1","author":"Triozzi","year":"2014","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0460","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ajo.2009.01.023","article-title":"Effectiveness of treatments for metastatic uveal melanoma","volume":"148","author":"Augsburger","year":"2009","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0465","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1097\/CMR.0000000000000242","article-title":"The use of pembrolizumab for the treatment of metastatic uveal melanoma","volume":"26","author":"Kottschade","year":"2016","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0470","doi-asserted-by":"crossref","first-page":"9588","DOI":"10.1200\/JCO.2016.34.15_suppl.9588","article-title":"Activity of anti-PD1\u00a0drugs in uveal melanoma patients","volume":"34","author":"Piperno-Neumann","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0475","doi-asserted-by":"crossref","first-page":"e0118564","DOI":"10.1371\/journal.pone.0118564","article-title":"Phase II DeCOG-study of ipilimumab in pretreated and treatment-na\u00efve patients with metastatic uveal melanoma","volume":"10","author":"Zimmer","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0480","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/CMR.0000000000000175","article-title":"A phase 2\u00a0study of tremelimumab in patients with advanced uveal melanoma","volume":"25","author":"Joshua","year":"2015","journal-title":"Melanoma Res"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0485","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1470-2045(17)30251-6","article-title":"Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2\u00a0study","volume":"18","author":"Chandran","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0490","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11\u00a0in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0495","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1001\/jama.2014.6096","article-title":"Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial","volume":"311","author":"Carvajal","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0500","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.74.1090","article-title":"Selumetinib in combination with dacarbazine in patients with metastatic uveal melanoma: a phase III, multicenter randomized trial (SUMIT)","author":"Carvajal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0505","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/bjc.2016.119","article-title":"Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study","volume":"115","author":"Mouriaux","year":"2016","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0510","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/bjc.2016.419","article-title":"Phase I randomised discontinuation trial of the MET\/VEGF receptor inhibitor cabozantinib in metastatic melanoma","volume":"116","author":"Daud","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0515","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/annonc\/mdt585","article-title":"Hepatic intra-arterial versus intravenous fotemustine in patients with liver metastases from uveal melanoma (EORTC 18021): a multicentric randomized trial","volume":"25","author":"Leyvraz","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2018.07.011_bib0260","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1245\/s10434-015-4968-3","article-title":"Results of a randomized controlled multicenter phase III Trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases","volume":"23","author":"Hughes","year":"2016","journal-title":"Ann Surg Oncol"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455118302327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T02:47:54Z","timestamp":1662000474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455118302327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":52,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0007455118302327"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.07.011","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prise en charge des m\u00e9lanomes oculaires, le minimum pour les oncologues","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2018.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}